Related Experiment Video
Updated: Aug 3, 2026

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
Published on: July 8, 2025
Lamotrigine for the treatment of bipolar spectrum disorder: a chart review
José M Montes1, Jerónimo Saiz-Ruiz, Guillermo Lahera
1Hospital Universitario Príncipe de Asturias, Universidad de Alcalá, Madrid, Spain. j_m_montes@hotmail.com
Background:
Bipolar spectrum disorders are highly prevalent and disabling but are often misdiagnosed and inadequately treated. The use of mood stabilizers may be an important treatment option. This study evaluated the effectiveness and safety of lamotrigine in bipolar spectrum patients.
Methods:
Retrospective follow-up of 34 charts of bipolar outpatients treated with lamotrigine in monotherapy or as add-on therapy. Clinic notes were used to score the Clinical Global Impression for Bipolar Disorders (CGI-BP-M) scale and to identify manic, hypomanic mixed or depressive relapses.
Results:
A mean dose of lamotrigine of 113.2+/-66.6 mg/day for a mean duration of 29.7+/-17.3 weeks (range 6-96 weeks) achieved remission on depression (score 1 on the CGI-BP-M depression subscale) in 47.1% of the patients. Eleven patients (32.4%) remained euthymic (score 1 on the CGI-BP-M overall subscale) during the follow-up, after initiating treatment with lamotrigine. Effectiveness of lamotrigine was greater for those patients diagnosed with bipolar spectrum disorders other than bipolar I. Lamotrigine was well-tolerated and only two patients discontinued due to side effects.
Limitations:
Chart review is open to several biases.
Conclusions:
In this sample of bipolar spectrum patients, lamotrigine was a safe and effective treatment.
More Related Videos
Related Concept Videos
Mania and Antimanic Drugs: Overview
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Therapeutic Drug Monitoring: Overview and Classification
Electroconvulsive Therapy

